Position in SVRA
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$18,407,216
-$2,670,624 QoQ
Shares Held
3,371,285
-3.6% QoQ
Ownership
1.65%
of shares outstanding
% of Portfolio
0.59%
of 13F equity value
Holder Rank
#17
of 184 holders
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 75.21707598141361.ToString("F0")%
Shared 0.ToString("F0")%
None 24.782924018586385.ToString("F0")%
Common Shares in SVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026EMERALD ADVISERS, LLC holds $427,347,303 across 25 Biotechnology names. SVRA ranks #11 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
1,588,132 | $61,127,200 | |
| 2 | TVTX |
Travere Therapeutics, Inc.
|
1,557,196 | $46,264,293 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
515,361 | $38,270,707 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
397,263 | $36,699,155 | |
| 5 | SYRE |
Spyre Therapeutics, Inc.
|
613,365 | $30,938,130 | |
| 6 | NKTR |
Nektar Therapeutics
|
394,604 | $28,391,757 | |
| 7 | KALV |
KalVista Pharmaceuticals, Inc.
|
1,264,023 | $25,444,782 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
1,839,566 | $21,946,022 |
All Filings in SVRA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $18,407,216 | 3,371,285 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $21,077,840 | 3,495,496 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $12,599,686 | 3,529,324 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $8,058,359 | 3,534,368 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $8,559,890 | 3,090,213 | Shares | Sole | 2025-05-01 | |
| 2024-12-31 | $7,161,327 | 2,332,680 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||